LIBLICENSE-L Archives

LibLicense-L Discussion Forum

LIBLICENSE-L@LISTSERV.CRL.EDU

Options: Use Forum View

Use Monospaced Font
Show HTML Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
From:
LIBLICENSE <[log in to unmask]>
Reply To:
LibLicense-L Discussion Forum <[log in to unmask]>
Date:
Thu, 14 Jun 2018 14:33:14 -0400
Content-Type:
multipart/alternative
Parts/Attachments:
text/plain (2080 bytes) , text/html (4 kB)
From: Richard Poynder <[log in to unmask]>
Date: Thu, 14 Jun 2018 18:35:48 +0100

The open-access publisher Dove Medical Press has a controversial past and I
have written about the company on a number of occasions.



When Dove was acquired by Taylor & Francis last September it was assumed
(by me at least) that controversy had become a thing of the past for the
publisher.



Seven months after the purchase, however, a medical technology company
called Minerva Surgical took the unusual step of publishing a press release
alleging that a paper published in Dove’s *International Journal of Women’s
Health* makes “material misleading statements” about the nature of a study
funded by a rival in “clear violation of the COPE guidelines.” As a result,
Minerva said, the paper should be retracted immediately.



To discuss this latest incident, Dove’s background, and some of the
“historical issues” the publisher has faced, Taylor & Francis’ Director,
Medicine and Open Access Deborah Kahn, agreed to do a Q&A with me, which I
have published on *Open & Shut?*.



Of the latest controversy Kahn says, “our investigations show that the peer
review was carried out to high standards and that the journal behaved well,
and the authors responses have satisfied us that the complaints are
unfounded.”



On the historical issues, she adds, the naysayers were wrong to have
doubted Dove’s probity. “We went through very detailed due diligence,
carrying out an extremely thorough process, when we acquired Dove Medical
Press. We were satisfied that, after some historical issues, improvements
had been made to their peer review process working with the OASPA
membership team … Eight months on from our acquisition, Dove are performing
well in all areas, we remain confident that we got value for money, and are
delighted that they are part of Taylor & Francis Group.”



The interview with Deborah Kahn can be read here:
https://poynder.blogspot.com/2018/06/the-oa-interviews-taylor-francis.html


ATOM RSS1 RSS2